Skip to main content
    P

    Passage Bio Inc (PASG)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.13
    -0.12 (-2.82%)

    Market Cap: $13.68M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Passage Bio Inc (PASG) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Passage Bio (PASG) to earn -$14.08 per share in the fiscal year ending Dec 31, 2026. Of 3 analysts, 1 rates the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$11.55.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.67, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 33% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy133.3%
    Hold266.7%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Hold
    Total analysts
    3

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$14.08
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$11.55
    EPS consensus
    Next report
    Mar 1, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$14.08-$14.08 to -$14.081
    Dec 31, 2027-$11.55-$11.55 to -$11.551

    Quarterly Estimates

    The EPS consensus rises from -$2.60 for the quarter ending Dec 31, 2026 to -$2.33 for the quarter ending Mar 31, 2027.

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$2.60N/A5
    Mar 31, 2027-$2.33-$4.06 to -$1.016

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202600
    Fiscal year ending Dec 31, 202700
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$11.34.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$14.08-$14.08-$11.34-$11.34-$11.34N/A
    Fiscal year ending Dec 31, 2027-$11.55-$11.55-$10.39-$10.39-$10.39N/A
    Quarter ending Mar 31, 2027-$2.33-$2.08-$1.93-$2.03-$2.02N/A

    Frequently Asked Questions About PASG

    What is the PASG stock forecast?

    Consensus analyst estimates put Passage Bio's EPS at -$14.08 for the fiscal year ending Dec 31, 2026. The consensus rating from 3 analysts is Hold.

    How do analysts rate PASG stock?

    Of 3 analysts covering Passage Bio, 0 rate it Strong Buy, 1 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from PASG next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$14.08, with estimates from -$14.08 to -$14.08 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$11.55, with estimates from -$11.55 to -$11.55 from 1 analyst.

    How many analysts cover PASG?

    3 analysts rate Passage Bio stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.